Tenax Therapeutics (TENX) Operating Expenses (2010 - 2026)
Tenax Therapeutics (TENX) posted quarterly Operating Expenses of $18.8 million for Q2 2026, up 59.29% year-over-year from $11.8 million in Q2 2025, and up 13.34% on a QoQ basis from $16.6 million in Q1 2026.
Tenax Therapeutics (TENX) Operating Expenses (2010 - 2026) Analysis & Trends
Tenax Therapeutics has reported Operating Expenses for 16 years, with the latest figure at $18.8 million in Q2 2026.
- Operating Expenses for Q2 2026 came in at $18.8 million, up 59.29% year-over-year; the trailing twelve-month figure through Jun 2026 was $68.6 million (up 95.79% YoY), and the FY2025 annual result was $56.4 million, up 189.24% from the prior year.
- Operating Expenses climbed to $18.8 million in Q2 2026, from $16.6 million in the prior quarter.
- Over five years, Operating Expenses peaked at $18.8 million in Q2 2026 and troughed at $1.2 million in Q2 2023.
- A 5-year average of $7.3 million and a median of $3.8 million in 2024 frame the typical range for Operating Expenses.
- The widest annual swing landed in 2022, when Operating Expenses tumbled 88.55%; it then soared 263.84% in 2025.
- A 5-year view of Operating Expenses shows it stood at $2.6 million in 2022, then jumped by 30.78% to $3.3 million in 2023, then soared by 118.35% to $7.3 million in 2024, then surged by 125.48% to $16.4 million in 2025, then grew by 14.2% to $18.8 million in 2026.
- Per Business Quant data, the three most recent Operating Expenses figures were $18.8 million in Q2 2026, $16.6 million in Q1 2026, and $16.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Tenax Therapeutics | 80.73 Mn | 80.73 Mn | - | 18.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.78 Mn |
| Mar 31, 2026 | 16.57 Mn |
| Dec 31, 2025 | 16.45 Mn |
| Sep 30, 2025 | 16.81 Mn |
| Jun 30, 2025 | 11.79 Mn |
| Mar 31, 2025 | 11.34 Mn |
| Dec 31, 2024 | 7.30 Mn |
| Sep 30, 2024 | 4.62 Mn |
| Jun 30, 2024 | 3.67 Mn |
| Mar 31, 2024 | 3.91 Mn |
| Dec 31, 2023 | 3.34 Mn |
| Sep 30, 2023 | 2.12 Mn |
| Jun 30, 2023 | 1.24 Mn |
| Mar 31, 2023 | 1.54 Mn |
| Dec 31, 2022 | 2.55 Mn |
| Sep 30, 2022 | 2.92 Mn |
| Jun 30, 2022 | 2.86 Mn |
| Mar 31, 2022 | 2.72 Mn |
| Dec 31, 2021 | 3.21 Mn |
| Sep 30, 2021 | 3.80 Mn |